Cited by 77Bariatric Surgery and OutcomesPancreatic function and diabetesDiabetes Management and Research

Prolonged Successful Therapy for Hyperinsulinaemic Hypoglycaemia after Gastric Bypass: The Pathophysiological Role of GLP1 and Its Response to a Somatostatin Analogue

Myint, K. S., Greenfield, J. R., Farooqi, I. S., Henning, E., Holst, J. J., Finer, N.·2012·European Journal of Endocrinology

Abstract

Background Spontaneous hyperinsulinaemic hypoglycaemia following gastric bypass surgery (GBS) is increasingly recognised. However, its pathophysiology remains unclear. Some patients require pancreatectomy. Medical therapy with calcium channel blockers, acarbose and diazoxide has been reported to be beneficial but has variable adherence and response. Method We demonstrate the role of GLP1, counter-regulatory hormones and the subsequent response of GLP1 to somatostatin analogue therapy in a 42-year-old woman with persistent neuroglycopaenia 6 years after GBS. Plasma GLP1, insulin and glucose were measured for 5 h on three settings: i) a 75 g oral glucose tolerance test (OGTT); ii) a standard liquid test meal (LTM); and iii) an OGTT 30 min after a s.c. injection of 100 μg octreotide. Results In comparison with obese non-diabetic controls, the patient had an elevated fasting and a markedly enhanced GLP1 response during the OGTT, followed by an exaggerated insulin response and a subsequent low glucose level. The GLP1 response to a LTM was similar but greater. Octreotide given prior to the OGTT attenuated both the GLP1 and insulin responses and abolished hypoglycaemia. Octreotide therapy significantly improved the patient's neuroglycopaenic symptoms. The hormone profile was reassessed after 6 months following the LTM preceded by octreotide injection. Peak GLP1 and insulin responses were less pronounced than pretreatment responses and without hypoglycaemia. The patient was treated w…

Integrity signals

Registry

Crossref · 10.1530/eje-11-1065

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Myint, K. S., Greenfield, J. R., Farooqi, I. S., Henning, E., Holst, J. J., & Finer, N.
Affiliations
  • University of Cambridge (GB)
  • University of Copenhagen (DK)
Corresponding author
Myint, K. S.
Venue
European Journal of Endocrinology
Published
2012-03-09
Volume
166
Issue
5
Pages
951-955
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W2114161811
Cited by
77
References
9
Citations by year
2026: 1 · 2025: 1 · 2024: 4 · 2023: 6 · 2022: 6 · 2021: 6 · 2020: 7 · 2019: 6 · 2018: 5 · 2017: 3 · 2016: 9 · 2015: 7 · 2014: 9 · 2013: 4 · 2012: 2
FWCI
7.17
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Funders
Wellcome Trust
Topics
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
hyperinsulinemic hypoglycemia, gastric bypass, glucagon-like peptide-1, somatostatin analogues, octreotide, lanreotide, incretin response, counterregulatory hormones, insulin response, medical therapy
MeSH terms
Adult, Female, Humans, Somatostatin, Time Factors, Octreotide, Gastric Bypass, Congenital Hyperinsulinism, Nesidioblastosis, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review